Effects of microtubule inhibitors-taxol, vinblastine and estramustine on the growth and p53 gene expression in the hormone independent human prostatic JCA-1 cells.
Treatment of the JCA-1 prostate cells with different concentrations of microtubule inhibitors-taxol (paclitaxel) vinblastine, and estramustine-was accompanied by reduced cell growth and, correspondingly, characteristic morphological changes. The reduction of cellular proliferation was unlikely to be attributable to an inhibitory effect of the antimicrotubule agents on cell cycling, but was correlated with the decreased expression of the p53 gene. These results suggest that antimicrotubule agents may be considered as potentially complementary treatment modalities for patients with hormonally independent prostate cancer.
Darby
E
E
Department of Urology, New York Medical College, Valhalla 10595, USA.
An
S
S
Ng
C
C
Hsieh
T C
TC
Mallouh
C
C
Wu
J M
JM
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004961:Estramustine / Q000494:pharmacology*; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000187:drug effects* / Q000378:metabolism; D017239:Paclitaxel / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology*; D014407:Tumor Cells, Cultured / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000187:drug effects* / Q000378:metabolism; D014747:Vinblastine / Q000494:pharmacology*
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D016159:Tumor Suppressor Protein p53; D004961:Estramustine; D014747:Vinblastine; D017239:Paclitaxel